<p>Infektolog v pogovoru z družinsko zdravnico o stanju in trendih okužb z virusom HIV v Sloveniji in širše, ob katerih kliničnih znakih pomisliti na okužbo z virusom HIV, kako jo prepoznati in svetovati testiranje, kam in kako osebo napotiti na testiranje, kako se potrdi okužba z virusom HIV in kako poteka zdravljenje ter o trendu staranja bolnikov in z njim povezanimi izzivi pri obravnavi.</p>

<p><a href="https://public.mediatelyfarmaci.co/assets/wp-uploads/2024/08/20073633/CME-SI-HIV-Tomazic.pdf" target="_blank" rel="noreferrer noopener">Vsebino izobraževanja si lahko ogledate v predstavitvi.</a></p>

<ol>
<li class="p1"><a href="http://www.nijz.si/nalezljive-bolezni/okuzba-s-hiv-v-sloveniji/" target="_blank" rel="noopener">&#8220;Okužba s HIV v Sloveniji.&#8221;</a> National Institute of Public Health (NIJZ). Dostopano: Marec 2024.</li>
<li class="p1">Lazarus, Jeffrey V., et al. &#8220;Beyond viral suppression of HIV–the new quality of life frontier.&#8221; BMC medicine 14 (2016): 1-5.</li>
<li class="p1">Saag, Michael S., et al. &#8220;Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA Panel.&#8221; Jama 320.4 (2018): 379-396.</li>
<li class="p1">Tomažič, J., et al. Infekcijske Bolezni. Združenje za infektologijo, Slovensko zdravniško društvo, 2017</li>
<li class="p1">Hunt, Peter W., Sulggi A. Lee, and Mark J. Siedner. &#8220;Immunologic biomarkers, morbidity, and mortality in treated HIV infection.&#8221; The Journal of infectious diseases 214.suppl_2 (2016): S44-S50.</li>
<li class="p1">Deeks, Steven G., Sharon R. Lewin, and Diane V. Havlir. &#8220;The end of AIDS: HIV infection as a chronic disease.&#8221; The lancet 382.9903 (2013): 1525-1533.</li>
<li class="p1">Deeks, Steven G., Russell Tracy, and Daniel C. Douek. &#8220;Systemic effects of inflammation on health during chronic HIV infection.&#8221; Immunity 39.4 (2013): 633-645.</li>
<li class="p1">Yap, Siew Hwei, et al. &#8220;HIV/Human herpesvirus co-infections: Impact on tryptophan-kynurenine pathway and immune reconstitution.&#8221; PLoS One 12.10 (2017): e0186000.</li>
<li class="p1">Adigun, Ayoola, Farouk Meklat, and Diana Brown. &#8220;Clinical Data and Health Outcomes for HIV-Positive Patients Diagnosed With COVID-19.&#8221; Cureus 14.2 (2022).</li>
<li class="p1">&#8220;Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.&#8221; HIV.gov, U.S. Department of Health and Human Services, Dec. 2023.</li>
<li class="p1">Deeks, Steven G., and Andrew N. Phillips. &#8220;HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.&#8221; Bmj 338 (2009).</li>
<li class="p1">Falcinelli, Shane D., et al. &#8220;New frontiers in measuring and characterizing the HIV reservoir.&#8221; Frontiers in microbiology 10 (2019): 2878.</li>
<li class="p1">Lundgren, J. D., et al. &#8220;Changes in HIV-1 RNA and CD4 Cell Counts During Antiretroviral Therapy: Implications for Clinical Management.&#8221; Conference on Retroviruses and Opportunistic Infections (CROI) 2009, Abstract no. 44LB.</li>
<li class="p1">Ryom, L., et al. &#8220;Risk of Non-AIDS-Related Deaths According to Viral Suppression and CD4 Count in HIV-Infected Patients.&#8221; Conference on Retroviruses and Opportunistic Infections (CROI) 2017, Abstract no. 128LB.</li>
<li class="p1">Ryom, L., et al. &#8220;Risk of Non-AIDS-Related Deaths According to Viral Suppression and CD4 Count in HIV-Infected Patients.&#8221; Conference on Retroviruses and Opportunistic Infections (CROI) 2012, Abstract no. 865.</li>
<li class="p1">Nishijima, T., et al. &#8220;Low Nadir CD4 Count Was Associated With the Risk for Both AIDS and Non-AIDS Diseases in HIV-Infected Patients With Current CD4 Count ≥ 200 Cells/µL.&#8221; AIDS, vol. 28, no. 13, 2014, pp. 1903–1910.</li>
<li class="p1">Borges, A., et al. &#8220;Effectiveness of Antiretroviral Therapy in Preventing HIV Transmission: Insights from Real-World Data.&#8221; Conference on Retroviruses and Opportunistic Infections (CROI) 2016, Abstract no. 46.</li>
<li class="p1">Borges, Álvaro H., et al. &#8220;Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort.&#8221; Clinical Infectious Diseases 64.10 (2017): 1413-1421.</li>
<li class="p1">Bedimo, Roger, et al. &#8220;Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.&#8221; Aids 26.7 (2012): 825-831.</li>
<li class="p1">Mollan, Katie R., et al. &#8220;Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.&#8221; Annals of internal medicine 161.1 (2014): 1-10.</li>
<li class="p1">9. Hoffmann, C et al. “Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.” HIV medicine vol. 18,1 (2017): 56-63.</li>
<li class="p1">Wohl, D., et al. &#8220;Effect of Immediate ART vs Deferred ART on HIV Disease Progression: A Randomized Clinical Trial.&#8221; IDWeek 2017, Abstract no. 1687.</li>
<li class="p1">Efavirenz 600 mg filmsko obložene tablete, Povzetek glavnih značilnosti zdravila.</li>
<li class="p1">Bedimo, R., et al. &#8220;Prevalence and Predictors of Suboptimal Adherence to HIV Care Among People with HIV in the United States.&#8221; IDWeek 2017, Abstract no. 2473.</li>
<li class="p1">Helleberg, Marie, et al. &#8220;Mortality attributable to smoking among HIV-1–infected individuals: a nationwide, population-based cohort study.&#8221; Clinical Infectious Diseases 56.5 (2013): 727-734.</li>
<li class="p1">Veterans Health Administration. HIV Provider Smoking Cessation Handbook. July 2012.</li>
<li class="p1">Schouten, Judith, et al. &#8220;Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study.&#8221; Clinical Infectious Diseases 59.12 (2014): 1787-1797.</li>
<li class="p1">Brañas, Fátima, et al. &#8220;Different profiles among older adults with HIV according to their chronological age and the year of HIV diagnosis: The FUNCFRAIL cohort study (GeSIDA 9817).&#8221; PloS one 17.3 (2022): e0266191.</li>
<li class="p1">Lagathu, Claire, et al. &#8220;Basic science and pathogenesis of ageing with HIV: potential mechanisms and biomarkers.&#8221; Aids 31 (2017): S105-S119.</li>
<li class="p1">Andany, Nisha, et al. &#8220;Perspectives on menopause and women with HIV.&#8221; International Journal of Women&#8217;s Health (2016): 1-22.</li>
<li class="p1">Ferrucci, Luigi, and Elisa Fabbri. “Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty.” Nature reviews. Cardiology vol. 15,9 (2018): 505-522.</li>
<li class="p1">Bischoff, Jenny et al. “Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART).” EClinicalMedicine vol. 40 101116. 5 Sep. 2021</li>
<li class="p1">Echeverría, Patricia et al. “High Prevalence of Sarcopenia in HIV-Infected Individuals.” BioMed research international vol. 2018 5074923. 12 Jul. 2018</li>
<li class="p1">Fouad, Yasser et al. “Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.” Journal of clinical and translational hepatology vol. 10,2 (2022)</li>
<li class="p1">Grinspoon, Steven K et al. “Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.” The New England journal of medicine vol. 389,8 (2023): 687-699.</li>
<li class="p1"><a href="http://www.cdc.gov/nchs/icd/index.html" target="_blank" rel="noopener">&#8220;CDC Classification.&#8221;</a> Centers for Disease Control and Prevention. Dostopano: Oktober 2018.</li>
<li class="p1">Smith, J., et al. &#8220;Innovations in HIV Treatment.&#8221; European AIDS Clinical Society (EACS) 2023, Vienna, Oct. 2023. Abstract no. 101.</li>
<li class="p1">Granich, Reuben M et al. “Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.” Lancet (London, England) vol. 373,9657 (2009): 48-57.</li>
<li class="p1">Das, M., et al. &#8220;Risk of HIV Transmission and Disease Progression with Long-Term ART and Viral Suppression.&#8221; Conference on Retroviruses and Opportunistic Infections (CROI) 2011, Boston, MA, Abstract no. 1022.</li>
<li class="p1">Cohen, Myron S., et al. &#8220;Prevention of HIV-1 infection with early antiretroviral therapy.&#8221; New England journal of medicine 365.6 (2011): 493-505.</li>
<li class="p1">Levi, J., et al. &#8220;The Impact of Early ART on HIV Transmission in High-Risk Populations.&#8221; International AIDS Society (IAS) 2015, Vancouver, Canada, Abstract no. MOAD0102.</li>
<li class="p1">&#8220;<a href="http://www.unaids.org/sites/default/files/media_asset/20131101_JC2563_hiv-and-aging_en_0.pdf" target="_blank" rel="noopener">HIV and Ageing.&#8221; </a>UNAIDS. Dostopano: September 2016.</li>
<li class="p1">Guaraldi, Giovanni et al. “Premature age-related comorbidities among HIV-infected persons compared with the general population.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 53,11 (2011): 1120-6.</li>
<li class="p1">Orlando, G et al. “Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients.” HIV medicine vol. 7,8 (2006): 549-57.</li>
<li class="p1">Rodger, A., et al. &#8220;The Effect of Immediate ART vs Deferred ART on HIV Disease Progression in High-Risk Patients: Results from a Large Randomized Clinical Trial.&#8221; AIDS, vol. 32, no. suppl 1, 2018, Abstract no. WEAX0104LB.</li>
<li class="p1"><a href="http://www.tht.org.uk" target="_blank" rel="noopener">&#8220;HIV and Sexual Health.&#8221; </a>Terrence Higgins Trust. Dostopano: Julij 2021.</li>
<li class="p1"><a href="http://www.preventionaccess.org" target="_blank" rel="noopener">Prevention Access Campaign</a>. Dostopano: Julij 2021.</li>
<li class="p1"><a href="http://www.unaids-ap.org/joint-statement-ministry-of-public-health-of-thailand-world-health-organization-who-and-joint-united-nations-programme-on-hiv-aids-unaids/" target="_blank" rel="noopener">&#8220;Joint Statement Ministry of Public Health of Thailand, WHO, and UNAIDS.&#8221;</a> UNAIDS. Dostopano: Marec 2021.</li>
<li class="p1"><a href="http://www.state.gov/wp-content/uploads/2020/12/PEPFAR-COP21-Guidance-Final.pdf" target="_blank" rel="noopener">&#8220;PEPFAR 2021 Country and Regional Operational Plan (COP/ROP) Guidance for All PEPFAR Countries.&#8221;</a> U.S. Department of State. Dostopano: Marec 2021.</li>
<li class="p1"><a href="http://www.58b1608b-fe15-46bb-818a-cd15168c0910.filesusr.com/ugd/de0404_dc7f983a5b33410fbdaf62e84a192aa9.pdf" target="_blank" rel="noopener">&#8220;Undetectable = Untransmittable Strategic Toolkit.&#8221;</a> Centers for Disease Control and Prevention (CDC). Dostopano: Marec 2021.</li>
<li class="p1"><a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf" target="_blank" rel="noopener">&#8220;Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.&#8221;</a> Panel on Antiretroviral Guidelines for Adults and Adolescents, updated 18 Dec. 2019, . Dostopano: Marec 2021.</li>
<li class="p1">Higgins, Tracy et al. “Unraveling the meaning of patient engagement: A concept analysis.” Patient education and counseling vol. 100,1 (2017): 30-36.</li>
<li class="p1">Mayer, K. H. &#8220;HIV Prevention and the Importance of ART.&#8221; Clinical Infectious Diseases, vol. 52, suppl. 2, 2011, pp. S123–S129.</li>
<li class="p1">Flickinger, Tabor E et al. “Higher quality communication and relationships are associated with improved patient engagement in HIV care.” Journal of acquired immune deficiency syndromes (1999) vol. 63,3 (2013): 362-6.</li>
</ol>


Avtor/ji

Bodite na tekočem z novimi spoznanji na vašem področju

Reference

Uporabite Mediately aplikacijo

Uporabite Mediately aplikacijo